Before joining ProSciento, he was Chief Operating Officer and, prior to that, Chief Financial Officer at UroGen Pharma, Ltd.. During his time at UroGen, he helped the company build its management team that successfully launched its first FDA-approved drug for urothelial cancer and completed a $160 million secondary offering. Before his executive leadership role at UroGen, Mr. Mullennix was Chief Financial Officer and Senior Vice President of Operations at SolarReserve, LLC, a solar energy technology company, where he supported the company’s expansion into more than 20 countries and oversaw multiple corporate financings. Prior to SolarReserve, Mr. Mullennix served as a Managing Director at US Renewables Group, a private equity investment fund with more than $750 million of assets under management.
He earned his MBA from the Anderson School at University of California Los Angeles and BA in Economic Geography from Dartmouth College.
